| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
GSK-J2 (CAS#: 1394854-52-4) showed the following inhibitory activities against various jumonji demethylases in enzymatic assays: KDM2B (IC50=8.3×10^{-6} M)
KDM3A (IC50>1.0×10^{-4} M) KDM3B (IC50>1.0×10^{-4} M) KDM4A (IC50>1.0×10^{-4} M) KDM4B (IC50>1.0×10^{-4} M) KDM4C (IC50>1.0×10^{-4} M) KDM5A (IC50>2.0×10^{-5} M) KDM5B (IC50=3.3×10^{-5} M) KDM5C (IC50=7.5×10^{-5} M) KDM6A (IC50>1.0×10^{-4} M) KDM6B (IC50=4.9×10^{-5} M) PHF8 (IC50=1.7×10^{-5} M). [1] GSK-J2 targets histone demethylases JMJD3/KDM6B and UTX/KDM6A, but with very poor activity compared to GSK-J1. It is considered the inactive enantiomer or regio-isomer of GSK-J1 and is used as a negative control in biological studies. |
|---|---|
| ln Vitro |
GSK-J2 is an isomer of GSK-J1, and it has weak activity (IC50 of > 100 μM and 49 μM, respectively) towards KDM6A and KDM6B[1].
In cell-based assays, GSK-J2 (CAS#: 1394854-52-4) showed no significant inhibition of KDM6B with an IC50 greater than 1.0 × 10^{-4} M. No other cellular activities were reported. [1] GSK-J2 shows poor inhibitory activity against KDM6A and KDM6B, with IC50 values greater than 100 µM and 49 µM, respectively. It is the isomer of GSK-J1 without any specific activity. The compound is used as a negative control in studies of GSK-J1 to demonstrate that effects are due to JMJD3/UTX inhibition rather than non-specific effects. |
| ln Vivo |
GSK J4 showed significant growth-inhibitory activity against SF8628 subcutaneous tumors.
In vivo activity is not expected for GSK-J2 as it is an inactive control compound. It has no significant biological activity and is used solely as a negative control in experiments with GSK-J1. |
| Enzyme Assay |
Enzymatic inhibition by GSK-J2 (CAS#: 1394854-52-4) was assessed using AlphaLISA-based assays. The panel of recombinant jumonji demethylases included truncated forms: KDM2B (amino acids 1-650), KDM3A (2-1322), KDM3B (842-1761), KDM4A (1-350), KDM4B (2-500), KDM4C (1-349), KDM5A (1-1090), KDM5B (1-809), KDM5C (2-1560), KDM6A (919-1401), KDM6B (1043-1643), and PHF8 (1-1024). The assays measured the half-maximal inhibitory concentration (IC50) values. Substrates and assay conditions were as described in the manufacturer's protocol but not detailed in the paper. [1]
Cell-free histone demethylase assays for GSK-J2 utilize purified recombinant JMJD3/KDM6B or UTX/KDM6A enzymes and histone H3 peptide substrates. The demethylation reaction is performed in the presence of increasing concentrations of the compound. Demethylation of H3K27me3 is quantified using radiometric, fluorescence, or mass spectrometry-based detection. IC50 values are determined to confirm lack of activity. |
| Cell Assay |
Cell-based assays for GSK-J2 (CAS#: 1394854-52-4) were performed using U2OS cells transfected with epitope-tagged KDM6B (amino acids 1026-1682), KDM5B (amino acids 1-752), or full-length KDM4C. Transfected cells were treated with varying concentrations of the compound. Demethylase activity was measured by immunodetection with antibodies recognizing H3K27me2 (for KDM6B), H3K4me2 (for KDM5B), and H3K9me3 (for KDM4C). IC50 values were determined as shown in Figure 1d. [1]
Cells are treated with GSK-J2 as a negative control alongside GSK-J1 treatment. H3K27me3 levels are assessed by Western blot or immunofluorescence. Gene expression changes are analyzed by qRT-PCR. Any effects observed with GSK-J2 would indicate non-specific or off-target effects, whereas specific effects would be observed only with GSK-J1. |
| Animal Protocol |
100 mg/kg/day; i.p.; for 10 days Mice harboring subcutaneous SF8628 K27M xenografts
In vivo animal studies are not typically performed with GSK-J2 as it is an inactive control compound. It may be used as a negative control in studies where GSK-J1 is administered to animals, to demonstrate that effects are due to specific JMJD3/UTX inhibition. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of GSK-J2 are not extensively characterized as it is an inactive control compound. As a small molecule (MW 389.45, formula C22H23N5O2), it is expected to have similar physicochemical properties to GSK-J1. The compound is soluble in DMSO (≥42 mg/mL).
|
| Toxicity/Toxicokinetics |
Toxicity data for GSK-J2 are not reported as it is an inactive control compound used in research. It is not intended for therapeutic use.
|
| References |
[1]. Heinemann B, et al. Inhibition of demethylases by GSK-J1/J4. Nature. 2014 Oct 2;514(7520):E1-2
|
| Additional Infomation |
3-[[2-(3-pyridyl)-6-(1,2,4,5-tetrahydro-3-benzozazepine-3-yl)-4-pyrimidinyl]amino]propionic acid is an organic nitrogen heterocyclic compound.
GSK-J2 (CAS#: 1394854-52-4) is an isomer of GSK-J1 and lacks specific inhibitory activity against the KDM6 subfamily. It was used as a negative control in the study. [1] GSK-J2 (molecular formula C22H23N5O2, MW 389.45) is the inactive regio-isomer of GSK-J1 used as a negative control in histone demethylase studies. It has poor activity against KDM6A and KDM6B. The compound is intended for research use only as a tool to distinguish specific JMJD3/UTX inhibition from non-specific effects. |
| Molecular Formula |
C22H23N5O2
|
|
|---|---|---|
| Molecular Weight |
389.45
|
|
| Exact Mass |
389.185
|
|
| CAS # |
1394854-52-4
|
|
| Related CAS # |
GSK-J1;1373422-53-7;GSK-J4;1373423-53-0;GSK-J5;1394854-51-3;GSK-J1 lithium salt
|
|
| PubChem CID |
73010924
|
|
| Appearance |
White to off-white solid powder
|
|
| LogP |
1.833
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
7
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
29
|
|
| Complexity |
517
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(O)CCNC1=NC(C2=CC=CN=C2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1
|
|
| InChi Key |
LJIFOCRGDDQFJF-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C22H23N5O2/c28-21(29)7-11-24-19-14-20(26-22(25-19)18-6-3-10-23-15-18)27-12-8-16-4-1-2-5-17(16)9-13-27/h1-6,10,14-15H,7-9,11-13H2,(H,28,29)(H,24,25,26)
|
|
| Chemical Name |
3-[[2-pyridin-3-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5677 mL | 12.8386 mL | 25.6772 mL | |
| 5 mM | 0.5135 mL | 2.5677 mL | 5.1354 mL | |
| 10 mM | 0.2568 mL | 1.2839 mL | 2.5677 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Inhibition of GSK-J1 and JIB-04.J Biol Chem.2016 Feb 5;291(6):2631-46. |
|---|
 Structural comparison of KDM5A and KDM6 family demethylases.J Biol Chem.2016 Feb 5;291(6):2631-46. |
 Overview of demethylation reactions catalyzed by KDM5 family.J Biol Chem.2016 Feb 5;291(6):2631-46. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA